Adherence to Iron Chelation Therapy Among Children with Beta Thalassemia Major: A Multicenter Cross-Sectional Study.

IF 1.2 4区 医学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY
Hemoglobin Pub Date : 2023-11-01 Epub Date: 2024-01-22 DOI:10.1080/03630269.2023.2295291
Thamron Keowmani, Siew Chin Teo, Kuan Chau Yap, Wei Lian Chua, Nur Farahanim Mohd Tahir, Peck Wei Chua, V Co Lim, Hoon Hing Leong
{"title":"Adherence to Iron Chelation Therapy Among Children with Beta Thalassemia Major: A Multicenter Cross-Sectional Study.","authors":"Thamron Keowmani, Siew Chin Teo, Kuan Chau Yap, Wei Lian Chua, Nur Farahanim Mohd Tahir, Peck Wei Chua, V Co Lim, Hoon Hing Leong","doi":"10.1080/03630269.2023.2295291","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Adherence to iron chelation therapy (ICT) remains an issue among thalassemia patients. This study aimed to determine the prevalence of non-adherence to ICT among children with beta thalassemia major in Malaysia and the factors associated with it.</p><p><strong>Methods: </strong>This was a cross-sectional study conducted between November 2019 and November 2021 at seven tertiary hospitals in Malaysia. Participants registered with Malaysian Thalassemia Registry were recruited by convenience sampling. Adherence was measured via pill count and self-reported adherence. Knowledge about thalassemia and ICT was measured using a questionnaire from <i>Modul Thalassemia</i> by Ministry of Health of Malaysia. A decision tree was used to identify predictors of non-adherence.</p><p><strong>Results: </strong>A total of 135 patients were recruited. The prevalence of non-adherence to ICT in those who took subcutaneous ± oral medications was 47.5% (95% CI: 31.5%, 63.9%) and the prevalence of non-adherence to ICT in those who took oral medications only was 21.1% (95% CI: 13.4%, 30.6%). The median knowledge score was 67.5% (IQR 15%). A decision tree has identified two factors associated with non-adherence. They were ICT's route of administration and knowledge score. Out of 100 patients who were on oral medications only, 79 were expected to adhere. Out of 100 patients who were on subcutaneous ± oral medications and scored less than 56.25% in knowledge questionnaire, 86 were expected to non-adhere. Based on the logistic regression, the odds of non-adherence in patients who took oral medications only was 71% lower than the odds of non-adherence in patients who took subcutaneous ± oral medications (OR = 0.29; 95% CI = 0.13, 0.65; <i>p</i> = .002).</p><p><strong>Conclusion: </strong>The prevalence of non-adherence to ICT among children with beta thalassemia major in Malaysia was 20/95 (21.1%) in those who took oral medications only and the prevalence of non-adherence was 19/40 (47.5%) in those who took subcutaneous ± oral medications. The factors associated with non-adherence were ICT's route of administration and knowledge score.</p>","PeriodicalId":12997,"journal":{"name":"Hemoglobin","volume":" ","pages":"237-244"},"PeriodicalIF":1.2000,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hemoglobin","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/03630269.2023.2295291","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/22 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Adherence to iron chelation therapy (ICT) remains an issue among thalassemia patients. This study aimed to determine the prevalence of non-adherence to ICT among children with beta thalassemia major in Malaysia and the factors associated with it.

Methods: This was a cross-sectional study conducted between November 2019 and November 2021 at seven tertiary hospitals in Malaysia. Participants registered with Malaysian Thalassemia Registry were recruited by convenience sampling. Adherence was measured via pill count and self-reported adherence. Knowledge about thalassemia and ICT was measured using a questionnaire from Modul Thalassemia by Ministry of Health of Malaysia. A decision tree was used to identify predictors of non-adherence.

Results: A total of 135 patients were recruited. The prevalence of non-adherence to ICT in those who took subcutaneous ± oral medications was 47.5% (95% CI: 31.5%, 63.9%) and the prevalence of non-adherence to ICT in those who took oral medications only was 21.1% (95% CI: 13.4%, 30.6%). The median knowledge score was 67.5% (IQR 15%). A decision tree has identified two factors associated with non-adherence. They were ICT's route of administration and knowledge score. Out of 100 patients who were on oral medications only, 79 were expected to adhere. Out of 100 patients who were on subcutaneous ± oral medications and scored less than 56.25% in knowledge questionnaire, 86 were expected to non-adhere. Based on the logistic regression, the odds of non-adherence in patients who took oral medications only was 71% lower than the odds of non-adherence in patients who took subcutaneous ± oral medications (OR = 0.29; 95% CI = 0.13, 0.65; p = .002).

Conclusion: The prevalence of non-adherence to ICT among children with beta thalassemia major in Malaysia was 20/95 (21.1%) in those who took oral medications only and the prevalence of non-adherence was 19/40 (47.5%) in those who took subcutaneous ± oral medications. The factors associated with non-adherence were ICT's route of administration and knowledge score.

重型β地中海贫血患儿坚持铁螯合疗法的情况:一项多中心横断面研究。
背景:地中海贫血患者对螯合铁疗法(ICT)的依从性仍然是一个问题。本研究旨在确定马来西亚重型β地中海贫血患儿不坚持ICT治疗的普遍程度及其相关因素:这是一项横断面研究,于2019年11月至2021年11月期间在马来西亚的七家三级医院进行。在马来西亚地中海贫血登记处登记的参与者是通过方便抽样的方式招募的。通过药片计数和自我报告的依从性来衡量依从性。有关地中海贫血和信息通信技术的知识则通过马来西亚卫生部地中海贫血模型问卷进行测量。采用决策树确定不坚持治疗的预测因素:结果:共招募了 135 名患者。在皮下注射和口服药物的患者中,未坚持使用信息通信技术的比例为 47.5%(95% CI:31.5%,63.9%),在仅口服药物的患者中,未坚持使用信息通信技术的比例为 21.1%(95% CI:13.4%,30.6%)。知识得分的中位数为 67.5%(IQR 15%)。决策树确定了与不坚持用药相关的两个因素。这两个因素分别是 ICT 的给药途径和知识得分。在 100 名仅使用口服药物的患者中,79 人有望坚持用药。在 100 名使用皮下注射药物和口服药物且知识问卷得分低于 56.25% 的患者中,预计有 86 人不会坚持用药。根据逻辑回归,只服用口服药物的患者不坚持用药的几率比服用皮下和口服药物的患者不坚持用药的几率低71%(OR = 0.29; 95% CI = 0.13, 0.65; p = .002):结论:马来西亚重型β地中海贫血患儿中,仅口服药物的患儿不坚持使用信息和通信技术的比例为20/95(21.1%),而皮下注射和口服药物的患儿不坚持使用信息和通信技术的比例为19/40(47.5%)。与不坚持服药相关的因素是信息和通信技术的给药途径和知识得分。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Hemoglobin
Hemoglobin 医学-生化与分子生物学
CiteScore
1.70
自引率
10.00%
发文量
59
审稿时长
3 months
期刊介绍: Hemoglobin is a journal in the English language for the communication of research and information concerning hemoglobin in humans and other species. Hemoglobin publishes articles, reviews, points of view The journal covers topics such as: structure, function, genetics and evolution of hemoglobins biochemical and biophysical properties of hemoglobin molecules characterization of hemoglobin disorders (variants and thalassemias), consequences and treatment of hemoglobin disorders epidemiology and prevention of hemoglobin disorders (neo-natal and adult screening) modulating factors methodology used for diagnosis of hemoglobin disorders
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信